Nce

Ami Organics gets 87 percent of the revenue comes from pharma space wherein it manufactures intermediates for APIs and NCE (New Chemical Entities). Rest of the revenue comes from chemicals segment. While company’s foray into the lithium-ion batteries and the semiconductor industry value chain is a key watch, ramp-up in CDMO (Contract Development and Manufacturing Organization) contracts is expected to be the key earnings catalyst. In the recent quarterly result, there was a sharp pick up in the CDMO business. At the same time, guidance for next three years suggest that high growth phase to sustain.

Zydus Lifesciences: Why we are getting constructive

There is a steady progress in product approvals and clinical trials for Zydus' niche products meant for rare ailments

Suven Life secures product patent in Japan

In a BSE filing today, Suven Life said it has been granted "one process patent from Japan corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases".

India may pay a hefty price for unplanned urbanisation, almost $1.8 trillion, by 2050: Study

If India continues with its current trend of ‘poorly planned, sprawling and unconnected‘ pattern of urbanisation, it could cost the country upto USD 1.8 trillion by mid-century, according to a new study from the &#82

Suven Life gains 6%, gets 5 patents for their NCE‘s

It has received these patents in Australia, China, Europe, South Korea and USA for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030,2031, 2030 and 2031 respectively.

Suven Life up 7%; bags 2 product patents in Europe & HK

The company has bagged one product patent from Europe and one product patent from Hong Kong.

Suven Life gets 4 patents; keen to enter Japan market

Suven Life Science has received patents for four of its new chemical entities (NCEs) in China, Mexico and New Zealand and the company also plans to very soon enter Japan market which is considered as next big opportunity for generic drug makers.

Although robust nos, analysts cautious of Glenmark

Glenmark Pharma reported stronger-than-expected numbers on all parameters as its consolidated net profit grew by 4.6 times year-on-year to Rs 213 crore in the third quarter of financial year 2012-13.

Dr Reddy's expands operations in UK

Pharma major Dr Reddy's Laboratories (DRL) today said it has expanded its manufacturing operations in the United Kingdom.

Suven Life gets 4 product patents for NCEs; stock up 4.3%

Suven Life Sciences has got 4 product patents for NCEs in Australia and Canada, reports CNBC-TV18.

Dr Reddy's scouts for new partners to develop NCE

Country's second largest drug maker Dr Reddy's Laboratories is looking for partners to develop its New Chemical Entity (NCE), an anti-cholesterol molecule, a top executive of DRL said today.

Cement firms capacity utilisation falls to 13-yr low

As per the data released by Cement Manufacturers Association, the Indian cement industry which is struggling with oversupply, witnessed a fall in capacity utilisation to a 13-year low of 83.9% for 2010-11, reports Business Standard.